ASX Biggest Risers Today

These companies are among the biggest ASX risers today as they drew strong investor attention due to the key recent operational developments in their growth trajectories.

Tanami Gold NL (ASX: TAM)

Tanami Gold NL (ASX: TAM) drew strong investor attention on Wednesday and the stock jumped 15% because gold prices moved higher amid geopolitical uncertainty which improved sentiment towards gold exploration companies.

The company is advancing the Central Tanami Project (CTP) in Australia through a joint venture which holds a mineral resource of about 31Mt at 2.8 g/t gold for about 2.8 million ounces which highlights the project’s scale and long-term potential.

The project also includes the high grade Groundrush deposit which contains about 11Mt at 3.3 g/t gold for around 1.2Moz which is supported by strong historical production and favourable metallurgy.

The site already has infrastructure which includes a CIL processing facility camp and airstrip which could reduce development costs and speed up the path toward production.

Sunrise Energy Metals Limited (ASX: SRL)

Sunrise Energy Metals Limited (ASX: SRL) surged over 17% by afternoon trade on Wednesday because investors had a positive reaction to the updates on its flagship Syerston Scandium Project.

The company recently completed a feasibility study which outlines a plan to produce about 60 tonnes per year of high purity scandium oxide which positions it as a potential major supplier outside China.

The project could require about US$120 million in development capital and could operate with life of mine operating costs of about US$534 per kilogram which places it among the lowest cost scandium producers globally.

Global demand for scandium could grow because it has applications in AI data centre power systems, aerospace alloys and advanced semiconductors.

Early site works and engineering activities are now underway while the company targets construction start later this decade and commercial production around 2028 if financing and development milestones proceed as planned.

Imugene Limited (ASX: IMU)

Imugene Limited (ASX: IMU) surged over 17% by afternoon trade on Wednesday as it continues to focus on advancing its key cancer therapy candidate azer-cel which has shown an 82% overall response rate in early clinical trials that target difficult-to-treat lymphoma patients.

Imugene also improved its financial position because it raised about $25 million through an institutional placement and share purchase plan which will fund ongoing clinical development programs.

The company as of 31 December 2025 held cash reserves of about $14.1 million which will support operations and research initiatives.

Imugene aims to progress clinical trials, expand partnerships such as its collaboration with JW Therapeutics and advance its pipeline of cancer immunotherapy treatments.

(Source: Company Reports)